Go Pro
→ Rothschilds and BlackRock are buying this high yield gold play (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.71
+3.3%		$3.83
$3.10
▼
$7.20
$6.92M1.0937,146 shs17,853 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$7.30
$7.30
$2.00
▼
$16.10
$11.72M1.185,025 shsN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.26
+4.2%		$11.61
$9.62
▼
$21.34
$765.11M0.0127,417 shs51,291 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+0.84%-9.37%-1.91%-15.73%-31.36%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%0.00%0.00%0.00%-40.11%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
+2.46%-0.09%-8.78%-16.01%-27.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.71
+3.3%		$3.83
$3.10
▼
$7.20
$6.92M1.0937,146 shs17,853 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$7.30
$7.30
$2.00
▼
$16.10
$11.72M1.185,025 shsN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.26
+4.2%		$11.61
$9.62
▼
$21.34
$765.11M0.0127,417 shs51,291 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+0.84%-9.37%-1.91%-15.73%-31.36%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%0.00%0.00%0.00%-40.11%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
+2.46%-0.09%-8.78%-16.01%-27.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.25
Hold$14.50290.84% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.20
Hold$38.67243.40% Upside

Current Analyst Ratings Breakdown

Latest BOLT, FNCH, OXB, and PHAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$37.00
9/14/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$37.00
8/7/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/3/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
7/31/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/30/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
7/17/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.70M0.93N/AN/A$13.81 per share0.27
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$376.13M2.12$0.21 per share53.90$3.95 per share2.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.44N/AN/AN/A-611.47%-126.23%-54.70%11/11/2026 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$2.85M$0.1293.8345.04N/A2.51%3.40%1.90%11/5/2026 (Estimated)

Latest BOLT, FNCH, OXB, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
7/30/2026Q2 2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$0.0630$0.02-$0.0430$0.02$99.52 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
1.47
2.61
2.61
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.34
3.01
2.31

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
231.93 million1.75 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
40770.78 million69.31 millionNot Optionable

Recent News About These Companies

Pharming Group's (PHAR) Buy Rating Reaffirmed at HC Wainwright
September 22 at 12:35 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-pharming-groups-phar-buy-rating-reaffirmed-at-hc-wainwright-2026-09-22/
Pharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026
September 22 at 9:05 AM  |  marketscreener.comM
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
September 22 at 9:05 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pharming-announces-positive-phase-ii-050000540.html
MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHAR
September 21 at 7:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-mac-alpha-capital-management-lp-makes-new-2984-million-investment-in-pharming-group-nv-sponsored-adr-phar-2026-09-21/
FY2027 EPS Estimates for Pharming Group Cut by HC Wainwright
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029678
Rhythm Pharmaceuticals (NASDAQ:RYTM) versus Pharming Group (NASDAQ:PHAR) Financial Comparison
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31028392
FY2026 EPS Estimates for Pharming Group Cut by HC Wainwright
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027650
Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?
September 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/pharming-group-phar-expands-joenjas-pediatric-label-can-growth-offset-ruconest-weakness-1837438/
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - What's Next?
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-sees-strong-trading-volume-whats-next-2026-09-16/
FY2027 EPS Forecast for Pharming Group Lowered by Analyst
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-fy2027-eps-forecast-for-pharming-group-lowered-by-analyst-2026-09-16/
HC Wainwright Reiterates Buy Rating for Pharming Group (NASDAQ:PHAR)
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025810
FY2026 EPS Forecast for Pharming Group Decreased by Analyst
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-fy2026-eps-forecast-for-pharming-group-decreased-by-analyst-2026-09-15/
Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946057-pharming-group-n-v-phar-presents-at-h-c-wainwright-28th-annual-global-investment-conference
Pharming Group's (PHAR) "Buy" Rating Reiterated at HC Wainwright
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-pharming-groups-phar-buy-rating-reiterated-at-hc-wainwright-2026-09-14/
Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja
September 14, 2026  |  marketscreener.comM
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharming-group-nv-sponsored-adr-nasdaq-phar-short-interest-update-2026-09-12/
Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
September 11, 2026  |  marketscreener.comM
Pharming Gets FDA Approval For Joenja In Children With APDS
September 11, 2026  |  rttnews.comhttps://www.rttnews.com/3690452/pharming-gets-fda-approval-for-joenja-in-children-with-apds.aspx
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
September 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-approves-pharming-joenja-first-180000437.html
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360484/0/en/fda-approves-pharming-s-joenja-as-first-treatment-for-children-with-apds-in-the-u-s.html
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell?
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-down-time-to-sell-2026-09-10/

Media Sentiment Over Time

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.71 +0.12 (+3.34%)
Closing price 04:00 PM Eastern
Extended Trading
$3.69 -0.02 (-0.43%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)
As of 09/21/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$11.26 +0.45 (+4.16%)
Closing price 04:00 PM Eastern
Extended Trading
$11.25 -0.01 (-0.09%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas